Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

August 15, 2025 Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
News
drug-trials

Novartis candidate for Sjögren’s disease presents positive results

August 15, 2025 Research and Development Immunology, Novartis, Sjögren’s disease, US Food and Drug Administration, clinical trial

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab in adults …
News

KIFFIK Biomedical expands leadership team with two executive appointments

August 14, 2025 Research and Development Chief Investment Officer, Corporate, Diagnostics, KIFFIK Biomedical, chief scientific officer

KIFFIK Biomedical has strengthened its leadership team with the appointments of Rene Veloso as chief investment officer and Reginald Swift …
Appointment

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

August 14, 2025 Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …
News
Patients image

PhotoPharmics expands Parkinson’s Trial into further US states

August 14, 2025 Research and Development Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders

US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites …
News

Medidata appoints Lisa Moneymaker as chief strategy officer

August 13, 2025 Clinical Trial Services, Research and Development Corporate, Medidata, chief strategy officer

Medidata has appointed Lisa Moneymaker as chief strategy officer to support the company’s long-term growth in the life sciences technology …
Appointment

CuraCell granted approval for trial of new therapy for metastatic cancers

August 13, 2025 Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
News
eye1

Eyestem secures $10m to advance cell therapy for advanced eye disease

August 13, 2025 Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy

Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
News

Enzymatica appoints Sana Alajmovic as new CEO

August 12, 2025 Research and Development Corporate, Enzymatica, Infections and infestations

The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …
Appointment
bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025 Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
News

ARTBIO expands board and establishes technical advisory board

August 11, 2025 Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …
Appointment
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025 Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
News

Horus Pharma expands distribution in North Africa and the Middle East

August 8, 2025 Mergers and Acquisitions, Research and Development Corporate, Horus Pharma, Opthalmology, distribution agreement

Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries …
News
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025 Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …
News
hospital

Sanome’s AI tool gains certification for early detection of hospital infections

August 7, 2025 Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections

Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026